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MCP-1 (monocyte chemoattractant protein-1) is a proinflammatory cytokine involved in che-
motaxis of monocytes. In several diseases, such as acute coronary syndromes and heart
failure, elevated MCP-1 levels have been associated with poor outcomes. Little is known
about MCP-1 in cirrhosis. AIM: To investigate the relationship between MCP-1 and outcome
in decompensated cirrhosis. METHODS: Prospective study of 218 patients discharged
from hospital after an admission for complications of cirrhosis. Urine and plasma levels of
MCP-1 and other urine proinflammatroy biomarkers: osteopontin(OPN), trefoil-factor3 and
liver-fatty-acid-binding protein were measured at admission. Urine non-inflammatory media-
tors cystatin-C, β2microglobulin and albumin were measured as control biomarkers. The
relationship between these biomarkers and the 3-month hospital readmission, complica-
tions of cirrhosis, and mortality were assessed. RESULTS: 69 patients(32%) had at least
one readmission during the 3-month period of follow-up and 30 patients died(14%). Urine
MCP-1 and OPN levels, were associated with 3-month probability of readmission (0.85
(0.27–2.1) and 2003 (705–4586) ug/g creat vs 0.47 (0.2–1.1) and 1188 (512–2958) ug/g
creat, in patients with and without readmission, respectively; p<0.05; median (IQR)). Fur-
thermore, urine levels of MCP-1 were significantly associated with mortality (1.01 (1–3.6) vs
0.5 (0.2–1.1) μg/g creat, in dead and alive patients at 3 months; p<0.05). Patients with
higher levels of urine MCP-1 (above percentile 75th) had higher probability of development
of hepatic encephalopathy, bacterial infections or AKI. Urine MCP-1 was an independent
predictive factor of hospital readmission and combined end-point of readmission or dead at
3 months. Plasma levels of MCP-1 did not correlated with outcomes. CONCLUSION: Urine,
but not plasma, MCP-1 levels are associated with hospital readmission, development of
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complications of cirrhosis, and mortality. These results suggest that in cirrhosis there is an
inflammatory response that is associated with poor outcomes.
Introduction
Increasing evidence suggest that there is a chronic inflammatory reaction in cirrhosis that may
play a role in determining patients outcome[1, 2]. This can be an aseptic inflammation, at least
in some patients, not related to the presence of detectable infections[3].Several lines of evidence
support this hypothesis. High levels of C-reactive protein (CRP) have been found in patients
with alcoholic cirrhosis without infections that correlate with liver dysfunction and mortality
[4]. In the large cohort of the Canonic study, leukocyte count was an independent predictive
factor of 3-month mortality regardless of the presence of detectable infection[5]. Moreover, the
presence of SIRS, with and without infection, has been associated with poor outcome in some
populations of patients with cirrhosis[6–8].
To gain a further insight in this hypothesis of presence and relevance of systemic inflamma-
tion in cirrhosis, we studied monocyte chemoattractant protein-1 (MCP-1) levels in a prospec-
tive study in a large series of patients with cirrhosis. MCP-1, also known as chemokine C-C
motif ligand 2 (CCL2), is a member of the chemokine family present in a large variety of cell
types (endothelial cells, fibroblasts, mononuclear cells) and is one of the most highly expressed
chemokines during inflammation[9, 10]. MCP-1 acts as a potent chemotactic factor that regu-
lates recruitment of monocytes to the inflammation site or tissue injury[11]. The role of sys-
temic MCP-1 has been evaluated in several chronic inflammatory states, and has been found to
be associated with poor outcomes[12–16]. Plasma levels of MCP-1 proved to be an indepen-
dent prognostic marker in acute coronary syndrome and also a predictor of all cause of mortal-
ity in patients with heart failure[12, 13]. Accumulating evidence from experimental studies
shows that MCP-1 compromises the integrity of the blood-brain barrier and modulates the
progression of various diseases in central nervous system disorders[14]. Evidence from human
studies also shows that there is immunochemical expression of MCP-1 in active lesions of mul-
tiple sclerosis in autopsied brains[10]. Moreover, MCP-1 modulates the inflammatory response
in renal diseases and increases inflammatory molecules on mesangial and tubular cells[15].
Finally, the inhibition of MCP-1 has been shown to ameliorate a variety of inflammatory renal
diseases, including diabetic nephropathy [16].
Hepatic gene expression of MCP-1 is increased in patients with chronic liver diseases[17].
MCP1 appears to play an important role in liver inflammation and fibrogenesis, driving mac-
rophage infiltration by binding CCR2 receptor[18–21]. However, compared to other chronic
diseases, little is known about systemic MCP-1 and cirrhosis. Increased levels of plasma MCP-
1 have been found in patients after large-volume paracentesis and also in patients with sponta-
neous bacterial peritonitis and are associated with derangement of circulatory function and
impaired survival, respectively [22, 23]. Moreover, we have previously shown that increased
urinary levels of MCP-1 are associated with the presence of acute-on-chronic liver failure
(ACLF)[24].
On this background, the current study was aimed at assessing the relationship between
MCP-1 and prognosis in decompensated cirrhosis. We analyzed urine and plasma levels of
MCP-1 in a prospective series of consecutive patients hospitalized for complications of cirrho-
sis and evaluated the probability of hospital readmission, development of complications, and
survival at 3 months. Our results show that urine but not plasma MCP-1 levels are associated
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This was a prospective study that included 218 consecutive patients with cirrhosis hospitalized
for management of an acute decompensation of the disease at the Liver Unit of Hospital Clinic
of Barcelona within a 2-year period. Patients were excluded from the study if: (1) had chronic
kidney disease treated with hemodialysis before admission, (2) had previous liver or kidney
transplantation, (3) had hepatocellular carcinoma beyond Milan criteria, (4) had advanced
chronic respiratory or heart disease (NYHA III and IV), and (5) had severe extrahepatic dis-
eases with poor short-term prognosis. Out of the 265 patients eligible during study period, 29
patients died and 5 were transplanted during hospitalization and 13 patients did not have urine
sample. Finally, we included 218 patients to assess the role of urine and plasma MCP-1 and
other urinary inflammatory mediators in predicting patient’s outcome after hospital discharge.
Study design
Demographical, clinical and analytical data were collected from all patients at study inclusion.
In addition, 10 mL of urine were obtained at inclusion to measure urine MCP-1 levels. In addi-
tion to MCP-1 we also measured other urinary inflammatory mediators, including osteopontin
(OPN), liver-fatty-acid-binding protein (LFABP), and trefoil-factor 3 (TFF3). These biomark-
ers were selected from a number of biomarkers on the basis of their association with patients
outcomes in a previous study from our group [24]. We also measured urinary β2-microglobu-
lin (β2M), Cystatin-C (Cys-C), and albumin levels as control non-inflammatory mediators. At
the same time of urine collection, 10 mL of blood were obtained to measure plasma levels of
MCP-1.
After discharge, patients were followed-up in the outpatient clinic for at least 3 months and
all complications of cirrhosis occurring during this period were recorded prospectively. All
patients gave written informed consent and the study was approved by the Institutional Review
Board Comitè Ètic d’Investigació Clínica del Hospital Clínic de Barcelona.
Urine samples were collected at 9 a.m. and centrifuged at 1000rpm for 10 minutes within
the first 4 hours and stored at -80° until use. MCP-1 and L-FABP were measured by Human
CCL2/MCP1 Quantikine ELISA Kit (R&D Systems) and Human L-FABP ELISA (Hycult Bio-
tech) respectively. Albumin measurement was performed by ADVIA ChemistryMicroalbu-
min_2 immunoturbidimetry method, enhanced with polyethylene glycol, (Siemens Healthcare
Diagnostics, Deerfield, IL). β2-microglobulin, cystatin C, osteopontin, and TFF- 3 were mea-
sured with RBM Human Kidney Toxicity Panel 2 according to the manufacturer protocol
(Bio-Rad Laboratories, Hercules, CA). Briefly, urine samples were centrifuged at 500 x g for 5
min and diluted 1:50 for the assays. After blockade of nonspecific binding sites, 30 microliters
of standards, controls or diluted samples were added to 96-well plates and incubated with 10
mL of fluorescently dyed magnetic microspheres covalently coupled to specific antibodies for
the desired biomarkers. Next, the plates were incubated for 1 h at room temperature and
washed three times with wash buffer. Afterwards, 40 mL of biotinylated detection antibody was
added to the wells and the plates were incubated for an additional hour at room temperature.
The final detection complex was formed with the addition of streptavidin-phycoerythrin con-
jugated. The median relative fluorescence units from the antibody reactions were acquired
using a Luminex 200 analyzer (Luminex, Austin, TX, USA) and the Bio-Plex Manager Software
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(v. 6.0; Bio-Rad Laboratories, Hercules, CA). The urinary biomarkers were indexed to urinary
creatinine for all analyses to adjust for variability in urine concentration.
Plasma samples were obtained at 9.a.m and centrifuged at 2000 rpm for 10 minutes and the
supernatant was stored at -80°C until analysis. MCP-1 was measured by Human CCL2/MCP-1
Quantikine ELISA (R&D Systems).
We examined the relationship between biomarkers and probability of 3-month hospital
readmission, 3-month mortality and a combined end-point of 3-month hospital readmission
and mortality. We also analyzed the relationship between these biomarkers and complications
of cirrhosis developing during follow-up period. Complications of cirrhosis were defined as
development of new-onset ascites or worsening of existing ascites (defined by increase of
diuretic therapy or need for large-volume paracentesis), hepatic encephalopathy (as assessed
clinically), bacterial infections, gastrointestinal bleeding or acute kidney injuri (AKI). The diag-
nosis of ascites, hepatic encephalopathy, bacterial infections and GI bleeding was made with
criteria reported elsewhere[25–28]. AKI was diagnosed according to AKIN criteria[27].
Statistical analysis
Continuous variables are presented as mean ± standard deviation or median (interquartile
range), and categorical variables are presented as number and percentage. We used indepen-
dent-sample t-tests to compare continuous variables and chi-square tests to compare categori-
cal variables. Kaplan-Maier method was used to estimate the frequency of readmission, death
and complications of cirrhosis during 3-month follow-up. The log-rank test was used to com-
pare outcomes between patients with MCP-1 levels above or equal to or below the 75th percen-
tile (MCP-1p75 or MCP-1<p75). The selection of a dichotomous threshold at 75th percentile
was retrospectively defined. Finally, a logistic regression model was created to identify the best
independent predictive factors of readmission and survival. All variables that were predictive
of outcomes at univarate analysis were included in the multivariate model. Urine MCP-1 was
introduced in the model as a dichotomous variable according to percentile 75th (MCP-1p75
or MCP-1<p75). Variables with skewed distribution were log-transformed before being
included in the multivariate analysis model. All statistical analyses were performed using SPSS
20.0 software. The significance level for all statistical tests was set at 0.05 two-tailed.
Results
Characteristics of the patient population
Demographic and clinical characteristics of the cohort are shown in Table 1. Patients had mod-
erate to severe impairment of liver function as reflected by high serum bilirubin, low serum
albumin, and mean MELD score of 16.
Biomarker levels and relationship with inflammatory parameters and
liver and kidney tests
Urine levels of biomarkers are presented in Table 1. In the whole series, urinary levels of MCP-
1 and albumin were increased compared to those of healthy subjects (MCP-1:0.54(0.2–1.4) vs
0.1(0.3–3.7) μg/g creat and albumin: 7.5(2–27) vs 1.3(0–2.1) mg/gcreat, both p<0.05). The
remaining urinary biomarkers were not increased with respect to normal values. We analysed
the relationship between urinary biomarkers and parameters of inflammation and liver and
kidney function tests. Inflammatory mediators (MCP-1, OPN, TFF-3 and L-FABP) had a
direct yet poor correlation with C-reactive protein (CRP) (r = 0.1, r = 0.16, r = 0.14 and
r = 0.17; p<0.05), but not with leukocyte count (except for L-FABP; r = 0.16; p<0.001). Urine
Urine MCP-1 an Inflammatory Biomarker of Prognosis in Cirrhosis
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MCP-1 had a negative correlation with albumin (r = - 0.14; p<0.001) and positive correlation
with INR and MELD score (r = 0.16 and r = 0.14, both p<0.001). There was a poor, but statisti-
cally significant, direct correlation between urine MCP1 and TFF-3 with serum creatinine lev-
els (r = 0.1 and r = 0.14, respectively; p<0.05). Moreover, there was a negative correlation
between urine Cys-C and β2M and serum creatinine levels (S1 Fig). With respect to plasma
Table 1. Demographic, clinical and laboratory data of the 218 patients included in the study.
VARIABLE
Age (years) 60 ± 12 (21–84)




Hepatic encephalopathy 33 (15%)
Non-SBP infections 36 (16%)
SBP 13 (6%)
GI bleeding 21 (9%)
Other 62 (28%)
Serum bilirubin (mg/dL) 5 ± 6 (0.3–32)
Serum albumin (g/L) 27 ± 5 (17–44)
INR 1.7±0.5 (0.9–4.4)
Serum creatinine (mg/dL) 1±0.6 (0.4–4)
Serum sodium (mEq/L) 135±6 (119–148)
Leukocyte count (109 cells/L) 6.2±4 (0.6–39)
CRP (mg/dL) 3.8 ±10 (0.02–129)
AKI* 50 (23%)
MELD score 16±7 (4–38)
Child Pugh:
Score 10 ± 2
Class A/B/C (%) 10% / 48% / 42%
Plasma MCP-1 (pg/mL) 248 (197–331)
Urine biomarkers:
MCP-1 (μg/g creat) 0.54 (0.2–1.4)
OPN (μg/g creat) 1466 (532–3461)
TFF-3 (μg/g creat) 1032 (448–3046)
LFABP (μg/g creat) 20 (8–46)
Albumin (mg/g creat) 7.5 (2–27)
Cys-C (μg/g creat) 36.2 (14–81)
β2M (μg/g creat) 90 (25–288)
Data are expressed as mean±SD and ranges or number and percentages. Biomarkers are expressed as
median (IQR). MCP-1: Monocyte chemoattractant protein 1, OPN: osteopontin, TFF3: Trefoil-factor3,
LFABP: Liver-fatty-acid-binding protein, Cys-C: cystatin C, β2M: β2microglobulin. Values of urine biomarkers
was measured in a subgroup of 6 healthy subjects (4 male, mean age of 59 ±8) and are as follows: MCP-1
0.1 (0.04–0.2) μg/g creat, Osteopontin 1416 (900–2025) μg/g creat, TFF-3 678 (466–951) μg/g creat,
Albumin 1 (0–2) mg/g creat, Cystatin C 32 (8–57) μg/g creat, β2-microglobulin 95 (9–132) μg/g creat [18],
LFAB-P 0.22±0.08 (mean ±SD). Levels of plasma MCP-1 were measured in a subgroup of 13 healthy
subjects: MCP-1 plasma: 210 (163–251) pg/mL *Etiologies of AKI were: pre-renal n = 20 (40%); Hepatorenal
syndrome n = 14 (28%); Acute tubular necrosis n = 7 (14%), Nephrotoxic drugs n = 5 (10%); Other n = 4 (8%)
doi:10.1371/journal.pone.0157371.t001
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MCP-1, patients with decompensated cirrhosis had higher levels compared to healthy subjects
(248 (196–331) vs 210 (163–254) pg/mL, p = 0.28). There was a significant direct correlation
between plasma MCP-1 levels and serum creatinine (r = 0.15; p<0.05. S1 Fig), bilirubin
(r = 0.13; p<0.05), and MELD score (r = 0.18; p<0.001). By contrast, no correlation was found
between plasma MCP-1 levels and other parameters of inflammation such as CRP levels or leu-
kocyte count.
Finally, we compared plasma and urine levels of MCP-1 and there was a poor direct correla-
tion between them (r = 0.13, p = 0.04; S1 Fig).
Biomarker levels and relationship with complications of cirrhosis at
hospital admission
Patients with ascites and HE at admission had significantly higher levels of urinary MCP-1 and
OPN compared to those of patients without these complications (0.73 (0.27–1.59) and 1688
(655–4240) vs 0.38 (0.15–0.74) and 1068 (283–2505) ug/g creat, p<0.001 for patients with
ascites; 0.79 (0.35–2.01) and 1990 (594–4757) vs 0.48 (0.20–1.08) and 1216 (508–3008), ug/g
creat, p<0.05 for patients with hepatic encephalopathy). By contrast, there were no significant
differences in urinary biomarker levels when patients with and without bacterial infections
were compared. Because of the statistically significant correlation between urine MCP-1 and
serum creatinine, we analyzed whether levels of urine MCP-1 and other biomarkers could be
related to kidney dysfunction. Patients were categorized according to quartiles of serum creati-
nine and the levels of each biomarker compared among the different quartiles. Urine TFF-3
levels increased significantly in parallel to quartiles of serum creatinine. By contrast, urine Cys-
C and β2M correlated inversely with serum creatinine levels (S1 Table). We also compared lev-
els of all urine biomarkers between patients with and without AKI at admission, and urine
TFF-3 was the only urine biomarker significantly increased in patients with AKI compared to
patients without AKI (S2 Table).
In contrast to the relationship between urine MCP-1 levels and some of the complications
of cirrhosis, there was no relationship between plasma MCP-1 and presence of complications
of cirrhosis at admission to hospital, except for higher plasma levels of MCP-1 in patients with
AKI compared to those of patients without AKI (S2 Table).
Biomarker levels and relationship with patient’s outcomes
Hospital readmission and mortality. At the end of 3-month follow period, 69 patients
(32%) had had at least one readmission to hospital for complications of cirrhosis. The most
common causes of readmission were bacterial infections and HE, which accounted for almost
half of all readmissions (17 patients and 13 patients, respectively). During the 3-month follow-
up period, 30 patients died (14%), 10 patients were transplanted, and 4 were lost to follow-up.
The main cause of death was acute-on-chronic liver failure, which occurred in 21 patients
(70%). Out of the total 218 patients, 78 patients (36%) developed the composite end-point of
3-month readmission or mortality.
Table 2 shows the univariate analysis of variables related to hospital readmission during the
3-month period. Besides liver tests and prognostic scores, urine MCP-1 and OPN levels were
significantly higher in patients who had at least one readmission to hospital compared to those
without readmissions. No other biomarkers were associated with hospital readmission. Of
note, plasma MCP-1 levels were similar in patients with readmission compared to those
without.
Table 3 shows the univariate analysis of variables related to 3-month mortality. Besides clin-
ical decompensations, liver tests, and prognostic scores, urinary MCP-1 and OPN levels were
Urine MCP-1 an Inflammatory Biomarker of Prognosis in Cirrhosis
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associated with mortality. No other urine biomarkers or plasma MCP-1 were associated with
mortality.
In multivariate analysis, the only independent predictive factors of hospital readmission
and combined end-point of hospital readmission or death were urine MCP-1 and MELD score
(Table 4).
Because urine MCP-1 was the only biomarker independently associated with readmission
and the combined end point of 3-month hospital readmission or mortality, we focused our
analyses on urine MCP-1 and its relationship with different outcomes. The characteristics of
patients according to quartiles of urine MCP-1 are shown in Table 5. Patients with urine MCP-
1 in the fourth quartile (MCP-1>p75) had more advanced liver disease, as indicated by greater
frequency of previous complications of cirrhosis (ascites, HE or infection), compared to those
in the other quartile groups.
There was a statistically significant difference of outcomes (readmission, death, composite
of death or readmission and complications) across the quartile groups of MCP-1 (Table 6).
Table 2. Univariate analysis of variables obtained at hospital admission associated with 3-month readmission during follow up.
No readmission (n = 149) Readmission (n = 69) p value
Age (years) 60±12 60±11 0.7
Sex (male) 98 (66%) 44 (63%) 0.6
Alcoholic Cirrhosis 70 (47%) 31 (45%) 0.7
Ascites 92 (62%) 54(78%) 0.02
Hepatic encephalopathy 41 (27%) 21(30%) 0.6
AKI 40 (33%) 22 (38%) 0.6
Non-SBP infection 25 (17%) 11 (16%) 1.0
SBP infection 10 (7%) 3 (4%) 0.7
Serum bilirubin (mg/dL) 4.2 ± 6.3 6.1 ± 7.2 0.05
Serum albumin (g/L) 27 ± 5 26 ± 4 0.3
INR 1.6 ± 0.5 1.8 ± 0.5 0.002
Serum creatinine (mg/dL) 1.0 ± 0.6 1.1 ± 0.6 0.6
Serum sodium (mEq/L) 135 ± 5 135 ± 4 0.7
CRP (mg/dL) 2 (1–3.7) 1.9 (0.6–4) 0.4
Leukocyte count (x109/L) 6.2 ± 4.5 6.4 ± 4.3 0.8
MELD score 15 ± 7 18 ± 7 0.003
Child-Pugh:
Score 9 ± 2 10 ± 2 0.002
Class A/B/C 12% / 54% / 34% 7% /36% / 57% 0.013
Plasma MCP-1 (pg/mL) 241 (193–341) 266 (200–331) 0.4
Urine Biomarkers:
MCP-1 (μg/g creat) 0.47 (0.2–1.07) 0.82 (0.3–2.0) 0.01
OPN (μg/g creat) 1188 (512–2958) 2003 (705–4586) 0.049
TFF3 (μg/g creat) 1582 (413–3894) 938 (462–2538) 0.1
LFABP (μg/g creat) 24 (11–70) 18 (7–41) 0.2
Albumin (mg/g creat) 12 (3–34) 7 (2–24) 0.2
β2M (μg/g creat) 83 (19–434) 94 (28–241) 0.6
Cys-C (μg/g creat) 34 (12–105) 39 (15–79) 0.7
Data are expressed as mean±SD, median (interquartile range) or number and percentages.CRP (C reactive protein), AKI (Acute kidney injury), SBP
(spontaneous bacterial peritonitis); MCP-1: Monocyte chemoattractant protein 1, OPN: osteopontin, TFF3: Trefoil-factor3, LFABP: Liver-fatty-acid-binding
protein, Cys-C: cystatin C, β2M: β2microglobulin.
doi:10.1371/journal.pone.0157371.t002
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However, a closer look at this relationship showed that outcome rates were quite similar in the
first three quartiles of MCP-1 levels, and increased markedly in the fourth quartile group
Table 3. Univariate analysis of variables obtained at hospital admission associated with 3-monthmortality during follow-up.
Alive (n = 188) Dead (n = 30) p value
Age (years) 60 ±11 60 ±12 0.9
Sex (male) 123 (65%) 18 (60%) 0.6
Alcoholic Cirrhosis, n (%) 86 (46%) 15 (50%) 0.8
Ascites 125 (66%) 21 (70%) 0.8
Hepatic encephalopathy 43 (23%) 19 (63%) <0.001
AKI* 48 (21%) 14 (58%) 0.02
Non-SBP infection 35 (18%) 1 (3%) 0.04
SBP infection 10 (5%) 3 (10%) 0.4
Serum bilirubin (mg/dL) 4.2 ±5 8.5 ± 8.6 0.01
Serum albumin (g/L) 27 ± 5 26 ± 5 0.5
INR 1.6± 0.5 2 ± 0.6 0.003
Serum creatinine (mg/dL) 1 ± 0.5 1.4 ± 0.8 0.01
Serum sodium (mEq/L) 135 ± 5 134 ± 3 0.3
Leukocyte count (x109/L) 5.8 ±4 8.6 ± 5 0.001
MELD score 14 ± 7 22 ± 7 <0.001
Child- Pugh:
Score 9 ± 2 11 ± 2 <0.001
Class A/B/C 11% / 53% / 36% 7% / 18% / 75% 0.001
Plasma MCP1 (pg/mL) 243 (195–331) 295 (226–338) 0.18
Urine Biomarkers:
MCP-1 (μg/g creat) 0.5 (0.2–1.1) 1.01 (1–3.6) 0.02
OPN (μg/g creat) 1315 (504–3269) 2324 (767–5497) 0.05
TFF3 (μg/g creat) 1012 (453–2772) 1929 (365–3895) 0.2
LFABP (μg/g creat) 18 (8–42) 21 (11–106) 0.1
Albumin (mg/g creat) 7 (2–27) 16 (4–74) 0.07
β2M (μg/g creat) 91 (27–272) 67 (10–379) 0.4
Cys-C (μg/g creat) 36 (14–78) 34 (9–188) 0.6
Data are expressed as mean±SD, median (interquartile range) or number and percentages.CRP (C reactive protein),
*AKI (Acute kidney injury), SBP (spontaneous bacterial peritonitis); MCP-1: Monocyte chemoattractant protein 1, OPN: osteopontin, TFF3: Trefoil-factor3,
LFABP: Liver-fatty-acid-binding protein, Cys-C: cystatin C, β2M: β2microglobulin.
doi:10.1371/journal.pone.0157371.t003
Table 4. Multivariate models of 3-month hospital readmission and combined end-point of 3-month
hospital readmission or death. Model 1. 3-month hospital readmission. Model 2. Combined end-point of
3-month hospital readmission or death.
Model 1 HR 95% IC p-value
Urine MCP-1p75 2.1 1.06–4.36 0.03
MELD 1.07 1.02–1.1 0.02
Model 2 HR 95% IC p-value
Urine MCP-1p75 2.4 1.19–4.88 0.01
MELD 1.08 1.03–1.1 0.001
Model 1: Variables included in the model: MELD score, CHILD score, urine MCP-1p 75th; Model 2:
Variables included in the model: MELD score, CHILD score, urine MCP-1p75
doi:10.1371/journal.pone.0157371.t004
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(Table 5). In fact, when compared with the first three quartiles, patients in the fourth quartile
had significantly higher probability of readmission (48% vs 26%; p = 0.001), death (24% vs
10%); p = 0.01), and composite end-point of readmission and death (54% vs 30%; p = 0.001)
(Fig 1).
Complications of cirrhosis during follow-up. During the 3-month follow-up period, 100
of the 218 patients (46%) developed a total of 181 complications of cirrhosis (Table 7). The
Table 5. Baseline characteristics of patients categorized according to quartiles of urine MCP-1.
Q1 (n = 53) Q2 (n = 55) Q3 (n = 56) Q4 (n = 54) p
MCP-1 range (ug/g creat) 0.01–0.22 0.23–0.54 0.55–1.43 1.44–26 —
Age 62 ±12 60 ±12 59 ±11 60 ±11 0.5
Male sex, n(%) 33 (58%) 32 (60%) 37 (69%) 39 (73%) 0.3
Diabetes Mellitus, n(%) 12 (21%) 14 (26%) 13 (25%) 14 (26%) 0.9
Arterial Hypertension 12 (21%) 10 (19%) 5 (9%) 10 (19%) 0.4
Etiology cirrhosis:
Alcohol 25 (44%) 25 (47%) 26 (49%) 25 (47%) 0.8
Hepatitis C 25 (44%) 26 (49%) 22 (42%) 23 (44%)
Previous decompensation:
Previous ascites, n(%) 33 (58%) 28 (53%) 43 (81%) 41 (77%) 0.002
Previous HE, n(%) 10 (17%) 16 (30%) 11 (21%) 24 (45%) 0.02
Previous infections, n(%) 6 (10%) 5 (9%) 8 (15%) 20 (37%) <0.001
Decompensation at admission:
Ascites 33 (58%) 28 (53%) 43 (82%) 41 (76%) 0.003
Hepatic encephalopathy 10 (17%) 16 (30%) 12 (23%) 25 (46%) 0.03
Infection non-SBP 10 (17%) 7 (13%) 9 (17%) 10 (18%) 0.8
SBP 5 (9%) 1 (2%) 4 (7.5%) 3 (6%) 0.4
AKI 10 (20%) 7 (15%) 8(19%) 15 (34%) 0.1
SIRS 24 (51%) 19 (35%) 17 (32%) 22 (40%) 0.5
Serum bilirubin (mg/dL) 4 ± 6 5 ± 7 5 ± 7 4 ± 6 0.7
Serum albumin (g/L) 28 ± 5 26 ± 4 26 ± 5 26 ± 5 0.05
INR 1.5 ± 0.5 1.6 ± 0.4 1.8 ± 0.6 1.8 ± 0.6 0.02
Serum creatinine (mg/dL) 1 ± 0.7 1 ± 0.5 1 ± 0.6 1.1 ± 0.6 0.7
Serum sodium (mEq/L) 135 ± 6 136 ± 4 134 ± 4 134 ± 4 0.2
Leukocyte count (109 cells/L) 5 ± 3 7 ± 5 6 ± 6 7 ± 4 0.2
CRP (mg/dL) 2.7 ± 4 3 ± 3 3.6 ± 4 3.2 ± 3 0.6
MELD score 14 ± 8 14 ± 6 17 ± 8 17 ± 8 0.05
Child-Pugh score 9 ± 2 9 ± 2 10 ± 2 10 ± 2 0.003
Data are expressed as mean±SD and ranges or number and percentages. SIRS: systemic inﬂammatory response; CRP: C- reactive protein. AKI at
admission was deﬁned according to AKIN criteria (21)
doi:10.1371/journal.pone.0157371.t005
Table 6. Outcomes according to quartiles of urine MCP-1.
Q1 Q2 Q3 Q4 p
(n = 53) (n = 55) (n = 56) (n = 54) value
MCP-1 range (μg/g creat) 0.01–0.22 0.23–0.54 0.55–1.43 1.44–26 —
3-month readmission 12 (23%) 14 (25%) 17 (32%) 26 (48%) 0.02
3-month mortality 5 (9%) 6 (11%) 6 (9%) 13 (24%) 0.09
3-month readmission or death 15 (28%) 14 (25%) 20 (36%) 29 (53%) 0.01
doi:10.1371/journal.pone.0157371.t006
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Fig 1. 3-month probability of hospital readmission, death and combined end-point of hospital
readmission or death in all patients categorized according to fourth quartile of urine MCP-1 levels.
doi:10.1371/journal.pone.0157371.g001
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most common complication was HE followed by bacterial infections. Urine MCP-1 levels were
significantly higher in patients who subsequently developed any complication during follow-
up compared to those of patients who did not This was true for all individual complications
except for ascites and gastrointestinal bleeding (Table 7). In contrast to differences observed in
urine MCP-1 levels, there were no significant differences in plasma MCP-1 between patients
who did and did not develop complications (Table 7). Fig 2 shows the 3-month probability of
development of HE, bacterial infections, and AKI in the whole population of patients divided
into two groups: patients within the first three quartiles (MCP1<p75) and patients within the
fourth quartile of urine MCP-1 (MCP-1p75). Patients in the fourth quartile of urine MCP-1
levels had higher probability of developing the later complications compared to patients in the
first three quartiles of MCP-1.
Of the 218 patients included in the study, 128 (58%) were treated with lactulose and 49
(22%) with rifaximin after hospital discharge for prevention of recurrent HE. The probability
of development of HE was higher in patients in the fourth quartile of urine MCP-1 in both sub-
groups of patients, those treated with lactulose and those with rifaximin, compared to the
remaining patients, yet the difference did not reach statistical significance (48% vs 32%,
p = 0.08, in patients treated with lactulose; and 69% vs 40%, p = 0.05 in patients treated with
rifaximin).
Because of the direct correlation between urine MCP-1 and serum creatinine, we repeated
all the analysis excluding patients with AKI at inclusion and found similar results. Urine MCP-
1 levels were higher in patients who had hospital readmission (0.82 (0.01–5.7) vs 0.46 (0.01–
19) μg/g creat; p = 0.02) or died within 3-months (1.24 (0.36–3.3) vs 0.49 (0.2–1.06) μg/g creat;
p = 0.03). Patients in the fourth quartile had higher probability of readmission or death during
the 3 month period of follow-up (S2 Fig). Urine levels MCP-1 were also a predictive factor of
Table 7. Urine and plasmaMCP-1 levels according to development of complications of cirrhosis during follow up.
COMPLICATIONS OF CIRRHOSIS Urine MCP-1 (μg/g creat) Plasma MCP-1 (pg/mL)
YES NO p YES NO p
Any complication (n = 100) 0.74 0.47 0.02 252 246 0.4
(0.23–1.96) (0.21–1.05) (205–313) (181–3419)
Hepatic encephalopath(n = 60) 0.93 0.48 0.01 256 246 0.5
(0.32–2.18) (0.2–1.12) (211–313) (195–332)
All infections (n = 44) 0.84 0.51 0.07 264 243 0.6
(0.26–3.15) (0.21–1.14) (195–316) (196–332)
SBP (n = 6) 4.28 0.51 <0.001 196 249 0.2
(3.75–7.42) (0.21–1.25) (111–317) (198–331)
Ascites (n = 34) 0.73 0.53 0.5 224 251 0.6
(0.2–2.09) (0.22–1.26) (197–314) (196–331)
All AKI (n = 30) 1.43 0.49 0.01 273 246 0.6
(0.41–3.72) (0.21–1.12) (190–362) (198–331)
HRS (n = 8) 2.8 0.51 0.005 281 246 0.7
(1.4–10.5) (0.21–1.24) (183–362) (194–331)
GI bleeding (n = 13) 1.24 0.54 0.2 200 250 0.07
(0.21–4.02) (0.22–1.37) (170–275) (199–331)
Data are expressed as median (interquartile range). Numbers in brackets after each complication represent the number of patients who developed each
complication during the 3-month follow-up period. SBP: spontaneous bacterial peritonitis. HRS: hepatorenal syndrome. GI bleeding: gastrointestinal
bleeding.
doi:10.1371/journal.pone.0157371.t007
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Fig 2. 3-month probability of EH, bacterial infections and AKI in all patients categorized according to
fourth quartile of urine MCP-1 levels.
doi:10.1371/journal.pone.0157371.g002
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combined end-point of hospital readmission or death in multivariate analysis (data not
shown).
Discussion
The main finding of the current study is that urine MCP-1 levels are associated with hospital
readmission and mortality within 3-months. MCP-1 is a potent chemoattractant protein highly
expressed in inflammatory states and higher levels have been associted with poor outcomes in
several chronic diseases. To our knowledge this is the first time that urinary levels of MCP-1
have been reported as associated with poor outcome in cirrhosis.
Patients with advanced cirrhosis may have increased blood leukocyte count, CRP levels,
pro-inflammatory cytokines, and systemic oxidative stress in the absence of infections, which
supports the hypothesis that there is a ‘sterile systemic inflammation’ in cirrhosis that may play
a role in the progression of the disease[1, 3–5, 8]. MCP-1 is one of the key chemokines that par-
ticipate in the recruitment of inflammatory cells and is highly expressed under inflamatory
conditions. The increased urine and plasma MCP-1 levels found in patients with decompen-
sated cirrhosis in the current study support the hypothesis of the existence of a systemic
inflammation in patients with advanced liver disease. In our series, patients with higher levels
of urine MCP-1 had higher probability of hospital readmission or death during follow-up com-
pared with patients with lower levels, suggesting that systemic inflammation in cirrhosis is
associated with poor outcomes.
An intriguing finding of our study was that whereas hospital readmissions, death, and com-
plications of cirrhosis were highly correlated with urine MCP-1 levels, no correlation was
found between these outcomes and plasma MCP-1 levels. The reason(s) for these apparently
inconsistent findings remains speculative. With the design of the current study, it is not possi-
ble to know whether the levels of MCP-1 found in the urine have a systemic origin, a kidney
origin or a combination of both. The systemic production of MCP-1 may theoretically be
increased as a result of the inflammatory syndrome characteristic of advanced cirrhosis, with
stimulation of the innate immune response[1, 29]. The MCP-1 originated in different organs
could then be in part eliminated through the kidneys by glomerular filtration because of the
low molecular size of the peptide (13kDa). To our knowledge, only few studies have been
reported assessing MCP-1 plasma levels in cirrhosis. In the first study, plasma levels of MCP-1
increased in association with changes in circulatory function after large-volume paracentesis in
a very small number of patients, suggesting monocyte activation in the context of large-volume
paracentesis induced circulatory dysfunction[22]. In a second study, plasma and ascitic levels
of MCP-1 were increased in patients with SBP compared to patients with cirrhosis without
SBP, and higher levels were associated with poor survival[23]. Finally, increased plasma levels
of MCP-1 were found in patients with cirrhosis and superimposed alcoholic hepatitis com-
pared to patients with cirrhosis without alcoholic hepatitis and healthy subjects. Although
plasma levels of MCP-1 correlated with disease severity, there was no relationship between
plasma levels and survival[30]. On the other hand, there is evidence that MCP-1 is produced in
the kidneys and the renal production of MCP-1 may be increased in a number of conditions,
including diabetic nephropathy and systemic lupus erithematosus [16]. In this regard, it is
interesting to note that there is an increased expression of toll-like receptor 4 in the renal
tubules in cirrhosis36-37. Therefore, it could be speculated that the increased endotoxin levels,
characteristic of advanced cirrhosis, may enhance the local production of MCP-1 in the kid-
neys via stimulation of toll-like receptors. The poor correlation observed in our study between
plasma and urine MCP-1 levels supports the existence of an increased renal production of
MCP-1 in cirrhosis. Nonetheless, regardless of the origin, the results of our study clearly
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indicate that urine but not plasma MCP-1 levels correlate with outcomes in patients with cir-
rhosis discharged from hospital after management of an acute decompensation of cirrhosis.
An interesting finding that deserves a comment is the association between MCP-1 levels
and the probability of developing complications during follow-up. In our series, urine MCP-1
levels were associated with an increased risk of HE. The pathophysiology of hepatic encepha-
lopathy is not completely understood but increasing evidence indicates that there is a synergis-
tic relationship between inflammation and ammonia in the pathogenesis of HE[31].
Inflammation can arise directly within the brain itself but may also originate in the peripheral
circulation and exert effects on the brain indirectly, via the release of pro-inflammatory media-
tors[32]. We hypothesize that besides being a biomarker of systemic inflammation, MCP-1
may also alter the integrity of the blood brain barrier, as it does in neurologic disorders,
decreasing the threshold for HE. In our series, urine MCP-1 levels correlated with the develop-
ment of bacterial infections, particularly SBP during follow-up. Our results are in keeping with
previous studies, where increased levels of MCP-1 were found in patients with SBP compared
to patients with ascites without SBP23. Finally, urine MCP-1 was also associated with the devel-
opment of AKI. The presence of severe inflammatory response has been previously associated
with development of HRS, a characteristic type of AKI in cirrhosis[33–35]. Findings derived
from human and experimental studies have shown that inflammation and infection in cirrhosis
lead to tubular damage and renal injury via up-regulation of renal tubular TLR4[36, 37]. It
could therefore be speculated that urine MCP-1 could be a marker of systemic inflammation
secondary to systemic and local production, and could be an early marker of kidney inflamma-
tion and anticipate the development of AKI in patients with cirrhosis.
The current study was performed in patients with cirrhosis hospitalized for management of
an acute decompensation. The exclusion of the patients who died during hospitalization is an
intrinsic bias of the study. In fact, we excluded patients who died during hospitalization
because the aim of the study was to analyse outcomes after discharge. Nevertheless, we
excluded patients with poorer prognosis and despite of this MCP-1 was a biomarker of progno-
sis in the remaining population. Due to the design of the study, we do not know if levels of
plasma or urine MCP-1 change over time and if these changes could predict more accurately
outcomes in these patients compared to a simple measurement, but this could be addressed in
future studies. MCP-1 has been reported as potential biomarker of kidney injury because its
expression is increased in kidney cells in experimental conditions of AKI[38]. Therefore, we
addressed the question of whether increased MCP-1 levels could be related to the existence of
AKI. Nonetheless, there was no statistical significant difference in MCP-1 levels between
patients with and without AKI. Moreover, MCP-1 levels did not show a progressive increase in
patients categorized according to quartiles of serum creatinine. Furthermore, MCP-1 levels
were still an independent predictive factor of poor outcome after exclusion of patients with
AKI. Therefore, it appears that increased urine levels of MCP-1 found in the current series of
patients were not related to the presence of AKI.
In summary, the results of the current study indicate that urine but not plasma MCP-1 lev-
els are associated with 3-month hospital readmission and mortality. These results suggest that
in cirrhosis there is an inflammatory response that is associated with poor prognosis.
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